NDAC Input Sought On Sunscreen Ingredient Data Necessary For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Nonprescription Drugs Advisory Committee will meet Sept. 4-5 to discuss the scope and safety of testing necessary for OTC sunscreen ingredients. The announcement comes after FDA earlier this year rejected time and extent applications to add new sunscreen actives to the OTC monograph.
You may also be interested in...
FDA Faults BASF Sunscreen Ingredient Data In Latest TEA Rejection
FDA advises BASF that the information the firm submitted is not sufficient to establish octyl triazone as GRASE. The agency’s third rejection this year of a sunscreen TEA could concern advocates on Capitol Hill and in the industry for using the process for adding ingredients to the OTC sunscreen monograph.
FDA Questions Spray Sunscreen Safety, Efficacy And Monograph Status
FDA could exclude increasingly popular spray sunscreens from the final monograph unless firms submit sufficient safety and efficacy data, according to an advanced notice of proposed rulemaking.
MHRA on herbals
"Using Herbal Medicines: Advice to Consumers" is a new guidance document issued July 27 that informs consumers about how to avoid low-quality products on the market, the UK's Medicines & Healthcare products Regulatory Agency announces. The document warns that "any medicine - herbal or otherwise - has the potential to have adverse effects," and states that the safe use of herbals "has not been established" in pregnant women, breastfeeding mothers, children or the elderly. MHRA also explains that products bearing a PL (product license) or THR (Traditional Herbal Registration) symbol on their product labels are regulated by the government, while products with no symbols have not been assessed by the agency. The guidance is being issued in the wake of MHRA's efforts to remove a number of questionable products from the market, including Real Herbs' supplement that was advertised to "inhibit the growth of tumor" and Rena Chinese Medical Center's capsule that claimed to have "strong effects in controlling HIV"...